Prolifagen Therapeutics is focused on cardiac regeneration through the innovative application of microRNA technology, specifically targeting the prevention of heart failure in patients who have experienced large myocardial infarcts. The company leverages the regenerative capabilities observed in lower vertebrates, such as zebrafish, which can regenerate heart tissue following injury. In contrast, mammals, including humans, exhibit limited cardiomyocyte proliferation post-injury. Prolifagen's research highlights the role of microRNA 302 (miR302) in promoting the proliferation of adult cardiac muscle cells, thereby facilitating the reconstitution of functional heart muscle after damage. This approach aims to enhance recovery and improve life quality following heart attacks, which affect a significant number of individuals annually.

The technology developed by Prolifagen involves the transient administration of miR302, which has been shown to effectively activate cardiomyocyte proliferation and restore cardiac function in preclinical models. Notably, the company has demonstrated that delivering miR302 via a shear-thinning hydrogel can protect the RNA and ensure its sustained release, further enhancing its therapeutic potential. Current research efforts include testing the efficacy of miR302 in a pig model of cardiac regeneration, supported by funding from the NIH Small Business Innovation Research Grant. This innovative approach not only aims to reduce scar size and improve heart function but also represents a significant advancement in the field of cardiac medicine, with the potential to transform treatment strategies for heart failure.

United States

Prolifagen Therapeutics is a biotech startup dedicated to the prevention of heart failure in patients with large myocardial infarcts. The company is focused on cardiac regeneration based on microRNA technology.

Prolifagen Therapeutics

Company Details